Overview

Our AFP SPEAR T-cell is aimed at the treatment of patients with hepatocellular carcinoma (HCC). A Phase I study is now open for enrollment in the United States.

Pipeline

Program Indications Pre-Clinical Phase I/II Registration
AFP Hepatocellular
Pre-Clinical Phase complete
Phase I/II Phase in progress
Registration Phase not started